The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...
Forbes contributors publish independent expert analyses and insights. I cover logistics and supply chain management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback